RO 7079901

Drug Profile

RO 7079901

Alternative Names: RO7079901

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 07 Jun 2017 Roche plans a phase I trial for Urinary tract infections in USA, Hungary, Latvia, Poland and Serbia (NCT03174795)
  • 01 Dec 2016 Roche initiates a phase I pharmacokinetics trial in USA (IV, Infusion) (NCT02975388)
  • 24 Nov 2016 Roche plans a phase I pharmacokinetics trial in USA (IV, Infusion) (NCT02975388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top